Investor Relations

Press Releases

Date Title and Summary View
Nov 17, 2015
PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive
Nov 09, 2015

Completion of the SECURE Clinical Trial for Twirla® Planned for Second Half of 2016; Resubmission to the FDA Planned for the First Half of 2017

Oct 19, 2015

Company Plans to Complete Clinical Trial in the Second Half of 2016 and File its Resubmission to the FDA in First Half of 2017

Sep 03, 2015
PRINCETON, N.J. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , President and Chief
Aug 31, 2015

Company on Track to Complete Study Enrollment for Its Combined Hormonal Contraceptive Patch by the End of Third Quarter 2015

Aug 27, 2015
PRINCETON, N.J. , Aug. 27, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that management will present at the following
Aug 13, 2015

Continues to Progress Clinical Trial; Patents for Proprietary Platform to Develop New Women's Contraceptive Products Allowed

Jul 23, 2015

Intellectual Property Portfolio Significantly Broadened for Its Proprietary Transdermal Delivery System

Jul 01, 2015

Presentation Scheduled on Wednesday, July 8th, 2015 at 11:15 AM ET

Jun 30, 2015
PRINCETON, N.J., June 30, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that its stock has been selected for addition to